Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710593 · ClinicalTrials.gov registry record · Phase 2
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
A Phase 2 study of HIV Infection, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT00710593: Completed Phase 2 study of HIV Infection, sponsored by University of North Carolina, Chapel Hill.
NCT00710593 is a Phase 2 study of HIV Infection that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 99 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (59% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00710593, a Phase 2 study of HIV Infection, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
Primary Outcome
The outcome measure for the primary objective is immunogenicity as measured by the GMT of HPV-6, -11, -16, -18 vaccine four weeks after the administration of vaccine dose #3, measured as a continuous variable. Vaccine dose # 3 was administered at Week 24.
Conditions Studied
Interventions
- BIOLOGICAL HPV vaccine for strains -6, -11, -16, and -18
Study Locations (14)
Florida
- Childrens Diagnostic & Treatment Center - Fort Lauderdale
- University of Miami School of Medicine - Miami
- USF College of Medicine - Tampa
Illinois
- Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital - Chicago
- Childrens Memorial Hospital - Chicago
New York
- Mount Sinai Medical Center - New York
- Montefiore Medical Center - The Bronx
California
- Childrens Hospital of Los Angeles - Los Angeles
District of Columbia
- Childrens National Medical Center - Washington D.C.
Louisiana
- Tulane University Health Sciences Center - New Orleans
Maryland
- University of Maryland - Baltimore
Pennsylvania
- Childrens Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00710593 record still lists
NCT00710593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (59% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV vaccine for strains -6, -11, -16, and -18 is the first listed.
NCT00710593 lists 14 locations in 10 states (Florida, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT00710593 about?
NCT00710593 is a clinical study titled "Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women". The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
What is the current status of trial NCT00710593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2008-02. Estimated completion is 2011-02.
What conditions does trial NCT00710593 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00710593?
The interventions under investigation include: HPV vaccine for strains -6, -11, -16, and -18 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00710593?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00710593 being conducted?
This trial has 14 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00710593's enrollment target sits among peer trials
99 27th of 73 higher than 47 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
-
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia